Status:
UNKNOWN
Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients
Lead Sponsor:
Xianmin Song, MD
Conditions:
NGS Monitor MRD
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation. Overview ...
Detailed Description
Minimal residual disease (MRD) detection is the detection of residual micro-clones in patients with leukemia in remission, predicting the recurrence of the disease, and determining the next treatment ...
Eligibility Criteria
Inclusion
- ≥18 years old, male or female;
- Patients who received allogeneic peripheral blood hematopoietic stem cell transplantation ;
- Patients must be able to understand and be willing to participate in this study and sign informed consent.-
Exclusion
- Non-allogeneic hematopoietic stem cell transplantation patients;
- The expected survival rate is less than 3 months after transplantation;
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04126967
Start Date
October 1 2019
End Date
December 31 2023
Last Update
October 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China, 200080